WHITEPAPER: IRT systems can be a double-edged sword. Set up properly, it can make your clinical supply strategy a breeze to execute. Set up improperly, it can apply additional pressure and stress to a sponsor’s resupply execution
WHITE PAPER: When pharmaceutical and biopharmaceutical companies engage in new product development, there is a historical tendency to focus on the immediate needs of the clinical phase. As a result, many commercialization-related decisions...
WHITEPAPER: When biotech and pharma companies transport investigational medical products (IMPs) internationally, they are often required to pay import
WHITEPAPER: A clinical distribution plan must be solid enough to begin planning activities, and flexible enough to adapt to inevitable changes. A good
WHITEPAPER: By its nature, EU compassionate use supply is needed urgently. This means packaging, labeling, and distribution must be executed rapidly and efficiently
WHITEPAPER: Tris Evans, Gavin Morgan, Uday Pathapati discuss what factors need to be considered from a quality, packaging and labeling, logistical and risk management perspective when planning an EU Compassionate Use Program...
When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?
Your bridge between life-changing therapies and patients
